These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 28043732

  • 1. Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway.
    Todd SM, Zhou C, Clarke DJ, Chohan TW, Bahceci D, Arnold JC.
    Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
    [Abstract] [Full Text] [Related]

  • 2. Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.
    Todd SM, Arnold JC.
    Br J Pharmacol; 2016 Jan; 173(1):53-65. PubMed ID: 26377899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
    Hempel BJ, Clasen MM, Nelson KH, Woloshchuk CJ, Riley AL.
    Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.
    Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS.
    Psychopharmacology (Berl); 2011 Nov; 218(2):443-57. PubMed ID: 21667074
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
    Hudson R, Renard J, Norris C, Rushlow WJ, Laviolette SR.
    J Neurosci; 2019 Oct 30; 39(44):8762-8777. PubMed ID: 31570536
    [Abstract] [Full Text] [Related]

  • 13. Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.
    Lazenka MF, Tomarchio AJ, Lichtman AH, Greengard P, Flajolet M, Selley DE, Sim-Selley LJ.
    J Pharmacol Exp Ther; 2015 Sep 30; 354(3):316-27. PubMed ID: 26099530
    [Abstract] [Full Text] [Related]

  • 14. Female but not male rats show biphasic effects of low doses of Δ9-tetrahydrocannabinol on anxiety: can cannabidiol interfere with these effects?
    Salviato BZ, Raymundi AM, Rodrigues da Silva T, Salemme BW, Batista Sohn JM, Araújo FS, Guimarães FS, Bertoglio LJ, Stern CA.
    Neuropharmacology; 2021 Sep 15; 196():108684. PubMed ID: 34181978
    [Abstract] [Full Text] [Related]

  • 15. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
    Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb 15; 269(1):17-35. PubMed ID: 30661105
    [Abstract] [Full Text] [Related]

  • 16. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
    Renard J, Loureiro M, Rosen LG, Zunder J, de Oliveira C, Schmid S, Rushlow WJ, Laviolette SR.
    J Neurosci; 2016 May 04; 36(18):5160-9. PubMed ID: 27147666
    [Abstract] [Full Text] [Related]

  • 17. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
    Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP.
    Neurosci Biobehav Rev; 2019 Dec 04; 107():696-712. PubMed ID: 31580839
    [Abstract] [Full Text] [Related]

  • 18. Absence of interaction between delta9-tetrahydrocannabinol (delta-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice.
    Ham MT, De Jong Y.
    Psychopharmacologia; 1975 Dec 04; 41(2):169-74. PubMed ID: 1171491
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
    Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T.
    Eur Neuropsychopharmacol; 2017 Dec 04; 27(12):1223-1237. PubMed ID: 29129557
    [Abstract] [Full Text] [Related]

  • 20. Sex-Dependent Synergism of an Edible THC: CBD Formulation in Reducing Anxiety and Depressive-like Symptoms Following Chronic Stress.
    Pérez-Valenzuela E, Hudson R, Uzuneser T, De Felice M, Szkudlarek H, Rushlow W, Laviolette SR.
    Curr Neuropharmacol; 2024 Dec 04; 22(12):2059-2078. PubMed ID: 37702237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.